A study to evaluate reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001481-16

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the reactogenicity of GSK Biologicals’ liquid HRV vaccine when compared to placebo in terms of grade “3” solicited adverse events (AEs).


Critère d'inclusion

  • Healthy volunteers (Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV))

Liens